MYD 内在价值评估与基本面分析 - Myriad Genetics Inc

自选股列表管理

自选股列表

股价: 5.868 EUR 5.46% 已休市

市值: €527.4百万

M	Myriad Genetics Inc XMUN:MYD	US

内在价值

数据不足，无法可靠地计算 Myriad Genetics Inc 的内在价值。

我们的估值真的有效吗？查看回测结果 .

生物技术 Health Care

Myriad Genetics 开发基因检测，帮助医生了解患者罹患某些疾病的风险，并更精准地选择治疗方案。其核心产品是实验室检测，涵盖遗传性癌症、女性健康等领域，以及一些用于评估个人对药物可能产生何种反应的药物基因组学检测。公司通过医生、医院和医疗系统销售这些检测，并在检测被开具并完成后获得收入。

Hereditary cancer testing Myriad sells DNA tests that look for inherited changes linked to cancer risk. The company helps doctors understand whether a patient may have a higher chance of developing certain cancers and may need closer screening or prevention plans.
Women’s health testing Myriad offers genetic tests used during pregnancy and around reproductive health care, including screening that helps doctors assess risks for the mother or baby.
Mental health and medication testing Myriad provides tests that help doctors choose medicines by looking at how a patient may respond to certain psychiatric drugs. These tests are used to support treatment decisions for depression, anxiety, and related conditions.